4 results about "Amycolatopsis" patented technology

The application discloses a genetically engineered bacterium for producing A82846B, namely, an engineered bacterium in which endogenous genes GrtfA, Lfp, or a combination of GrtfA and Lfp are integrated in the genome of a starting bacterium Amycolatopsis orientalis. The application also discloses a construction method of the genetically engineered bacterium, and a method for fermenting the genetically engineered bacterium and obtaining A82846B from a fermentation liquor. The genetically engineered bacterium overexpresses the introduced endogenous genes GrtfA, Lfp, or the combination of GrtfA and Lfp, and produces A82846B, thereby improving the yield of A82846B and the proportion of A82846B in total products, achieving the positive effects of improving the production efficiency of the target product A82846B, reducing the production cost, and reducing environmental pollution.

The invention relates to the technical field of agricultural microorganisms, and in particular relates to a tea tree phyllostachys paratacidophilus BFI-L14 and application thereof. The invention discloses a tea tree interleaf paratyphagus acid bacterium BFI-L14, which is paratyphagus oryzae, and the preservation number of the tea tree interleaf paratyphagus acid bacterium BFI-L14 is CGMCC (China General Microbiological Culture Collection Center) No.35900. Volatile substances released by the strain have multiple effects of preventing and treating anthracnose of tea trees, promoting growth of arabidopsis thaliana and the like.

The invention relates to the technical field of microbial medicines, and in particular relates to a novel angular anthracycline compound Thioangucycline A, which is separated from a fermentation extract of an actinomycete of Amycolatopsis and has anti-tumor and antibacterial activities. The invention also relates to a preparation method of the novel angular anthracycline compound Thioangucycline A. The preparation method of the novel angular anthracycline compound Thioangucycline A comprises the following steps of: separating the novel angular anthracycline compound Thioangucycline A; an in-vitro anti-tumor test shows that the compound Thioangucycline A has a very strong inhibition effect on a human cervical cancer cell HeLa and a human leukemia cell U937. An in-vitro antibacterial test shows that the compound Thioangucycline A has an obvious antibacterial effect on gram-positive bacteria staphylococcus aureus and bacillus subtilis, so that the compound can be used for preparing an anti-tumor or antibacterial drug. The invention provides a new lead compound for developing anti-tumor and antibacterial drugs, and provides a scientific basis for developing and utilizing microbial drug resources.

This invention discloses *Amycolatopsis* sp., its culture, metabolites, bacterial agents, and applications. The *Amycolatopsis* sp. provided by this invention has strain number TRM77291 and accession number CCTCC M 2024327 at the China Center for Type Culture Collection. This strain exhibits antibacterial activity against Erwinia, Salmonella, *Escherichia coli*, and *Pseudomonas aeruginosa*. This invention is of significant importance for the control of Gram-negative bacterial infections and the research of novel actinomycete-derived drugs.